Biomarin Pharmaceutical Inc. ((BMRN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioMarin Pharmaceutical Inc. is conducting a study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)’. The study aims to assess the safety and tolerability of a single oral dose of BMN 349 in adult participants with specific genetic mutations, focusing on adverse events and laboratory test abnormalities.
The intervention being tested is BMN 349, a 250mg oral tablet, alongside a placebo. These are administered to evaluate their safety and pharmacokinetics in the target population.
The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to ensure the safety of BMN 349.
The study commenced on February 21, 2025, with its primary completion and estimated overall completion dates yet to be determined. The most recent update was submitted on July 1, 2025, indicating ongoing recruitment.
This study update could influence BioMarin’s stock performance positively, as successful trials may enhance investor confidence and market position. However, the competitive landscape in pharmaceuticals remains challenging, with other companies also pursuing similar innovations.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.